Abstract
Purpose/Objective
To compare toxicity profiles of low-dose rate (LDR) and high-dose rate (HDR) brachytherapy
boost combined with ultra-hypofractionated external beam radiation therapy (UH-EBRT).
Materials/Methods
99 patients with intermediate-risk prostate cancer underwent an HDR (n = 59) or LDR (n = 40) boost combined with UH-EBRT (5 Gy x 5) . HDR (Ir-192) was delivered a single
dose (15 Gy) and LDR (Pd-103) prescription dose was 100 Gy. Median baseline IPSS was
5 for both cohorts. Median follow-up was 29.3mos. Cumulative incidences were calculated
for toxicity. Fisher exact tests were used to evaluate associations.
Results
Overall incidence of grade 2 genitourinary toxicity for the entire cohort at 12 and
24 months was 21% and 29%, respectively. The incidence of grade 2 genitourinary toxicity
at 12 and 24 months was higher for LDR cohort compared with HDR cohort (45% vs 5.1%
and 55% vs 11%; p<0.001). On MVA, only treatment regimen (LDR versus HDR) was associated with grade
2+ genitourinary toxicity (p<0.001). Two patients experienced grade 2 rectal toxicity in each cohort. No grade
> 3 toxicities were observed.
Conclusions
Both LDR and HDR brachytherapy combined with UH-EBRT had favorable toxicity profiles,
but significantly less grade 2+ genitourinary toxicity was observed in patients receiving
HDR.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to BrachytherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Randomized trial comparing iridium implant plus external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate.J Clin Oncol. 2005; 23: 1192-1199
- Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results.Radiother Oncol. 2021; 154: 214-219
- Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): An analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer.Int J Radiat Oncol Biol Phys. 2017; 98: 275-285
- ASCENDE-RT: An analysis of health-related quality of life for a randomized trial comparing low-dose-rate brachytherapy boost with dose-escalated external beam boost for high- and intermediate-risk prostate cancer.Int J Radiat Oncol Biol Phys. 2017; 98: 581-589
- Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer.BJU Int. 2014; 114: 360-367
- Low-dose-rate brachytherapy combined with ultrahypofractionated radiation therapy for clinically, localized, intermediate-risk prostate cancer: Results from a prospective trial.Int J Radiat Oncol Biol Phys. 2020; 108: 905-913
- Early outcomes of high-dose-rate brachytherapy combined with ultrahypofractionated radiation in higher-risk prostate cancer.Brachy. 2021; 26: S1538-S4721
- Toxicity outcomes after low-dose-rate vs high-dose-rate brachytherapy boost in combination with external beam radiation for intermediate and high-risk prostate cancer.Int J Radiat Oncol Biol Phys. 2021; 111: e272
- A phase 2 randomized pilot study comparing high-dose-rate brachytherapy and low-dose-rate brachytherapy as monotherapy in localized prostate cancer.Adv Radiat Oncol. 2019; 4: 631-640
Article Info
Publication History
Published online: June 17, 2022
Accepted:
April 26,
2022
Received in revised form:
April 5,
2022
Received:
February 13,
2022
Publication stage
In Press Corrected ProofFootnotes
Disclosures: This research was funded in part through the National Institute of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748 .
Identification
Copyright
© 2022 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
